The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course.
Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases
Egidio ImbalzanoSecondo
Investigation
;Claudia MorabitoInvestigation
;Marianna Gigliotti De FazioInvestigation
;Pasquale CreaInvestigation
;Giuseppe Dattilo.Ultimo
Validation
2020-01-01
Abstract
The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
